论文部分内容阅读
应用ＬＳＡＢ免疫组化法，观察乳腺癌组织中ｂｃｌ－２蛋白表达，探讨其临床病理意义。结果显示，ｂｃｌ－２表达的阳性率为４２．７％，阳性反应物质位于细胞浆或核膜上，胞核中偶有表达。ｂｃｌ－２在乳腺癌组织中的表达与病人年龄、月经情况、肿瘤大小及淋巴结转移无明显关系（Ｐ＞０．０５）。浸润性小叶癌及浸润性导管癌之间，ｂｃｌ－２表达串的差异无显著性意义（Ｐ＞０．０５）。观察还发现，ｂｃｌ－２表达与显示预后好的某些病理形态学特征关系密切，浸润性导管癌不同病理分级组间，ｂｃｌ－２表达率有极显著性差异（Ｐ＜０．０１）；核分裂≥２１／１０高倍视野组，ｂｃｌ－２表达率明显低于０～１０／１０高倍视野组（Ｐ＜０．０１）；有肿瘤坏死者的ｂｃｌ－２表达率明显低于无肿瘤坏死者（Ｐ＜０．０１）。另外还观察到，ｂｃｌ－２与ｐ５３表达之间呈负相关（Ｐ＜０．０１），与ｃ－ｅｒｂＢ－２、ＭＤＲ１、ＧＳＴ－、ｎｍ２３及ＰＣＮＡ之间均无显著关系（Ｐ＞０．０５）。
LSAB immunohistochemistry was used to observe the expression of bcl-2 protein in breast cancer tissues and its clinicopathological significance was explored. The results showed that the positive rate of bcl-2 expression was 42.7%, and the positive reaction substance was located on the cytoplasm or nuclear membrane and was occasionally expressed in the nucleus. The expression of bcl-2 in breast cancer was not significantly related to the age, menstruation, tumor size and lymph node metastasis (P>0.05). There was no significant difference in bcl-2 expression between invasive lobular carcinoma and invasive ductal carcinoma (P>0.05). It was also observed that bcl-2 expression was closely related to certain pathological features showing good prognosis, and there was a significant difference in the expression of bcl-2 between different pathological grades of invasive ductal carcinoma (P<0.01). The bcl-2 expression rate was significantly lower in the ≥21/10 high power field group than in the 0～10/10 high power field group (P<0.01). The bcl-2 expression rate was significantly lower in those with tumor necrosis than in those without tumor necrosis. (P<0.01). In addition, it was also observed that there was a negative correlation between bcl-2 and p53 expression (P<0.01) and no significant relationship between c-erbB-2, MDR1, GST-, nm23 and PCNA (P>0. 05).